Works matching IS 10031057 AND DT 2023 AND VI 32 AND IP 2

Results: 11

The teams of Prof. Jiancheng Wang and Dong Jiang have made new progress in the field of remodeling inflammatory microenvironment for the treatment of osteoarthritis.

Published in:: Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 162
Publication type:: Article

The teams of Prof. Yimin Cui and Prof. Zhenming Liu have discovered a potential new treatment for castration-resistant prostate cancer that targets integrin receptors.

Published in:: Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 158
Publication type:: Article

The team of Prof. Luwen Shi and Prof. Xiaodong Guan has made progress in the innovation and clinical benefit evaluation of cancer drugs in China.

Published in:: Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 156
Publication type:: Article

The team of Prof. Ming Ma has made new progress in the structure and catalytic mechanism of furanose biosynthetase.

Published in:: Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 153
Publication type:: Article

Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 145, doi. 10.5246/jcps.2023.02.013

By:

Yuanchao Zhu;
Chen Chen;
Xin Hu

Publication type:

Article

Clinical efficacy and safety of levosimendan in patients with peripartum cardiomyopathy.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 138, doi. 10.5246/jcps.2023.02.012

By:

Fanfan Xu;
Huiping Gong;
Zengqiang Liu;
Qian Wu

Publication type:

Article

Pharmacovigilance evaluation of enfortumab vedotin using the FDA Adverse Event Reporting System.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 130, doi. 10.5246/jcps.2023.02.011

By:

Hui Yang;
Haozhou Wang;
Zhuoling An

Publication type:

Article

The opioid crisis in the United States and the strategies to address the epidemic.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 122, doi. 10.5246/jcps.2023.02.010

By:

Chang Wang;
Chen Jiang;
Jing Chen;
Chengliang Zhang

Publication type:

Article

Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 112, doi. 10.5246/jcps.2023.02.009

By:

Jia Ge;
Longfei Chen;
Xiaoyan Nie;
Jing Chen

Publication type:

Article

A cell-combining-oriented phytochemical screening strategy using triple quadrupole mass spectrometry for the investigation of potential bioactive candidates in Chinese traditional medicine preparation Xiao-ai-ping injection.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 101, doi. 10.5246/jcps.2023.02.008

By:

Zhi Rao;
Yuhui Wei

Publication type:

Article

Anti-oxidative and anti-neuroinflammatory effects of corylin in H<sub>2</sub>O<sub>2</sub>-induced HT22 cells and LPS-induced BV2 cells by activating Nrf2/HO-1 and inhibiting NF-κB pathways.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 2, p. 85, doi. 10.5246/jcps.2023.02.007

By:

Zhaojing Wang;
Qingxia Xu;
Jing Xu;
Wei Xu;
Xiuwei Yang

Publication type:

Article